Abstract: A color-light generation system includes a light source emitting first and second area light beams, a reflective grating receiving the first and second area light beams and then generating first and second area reflected light beams, an array optical switch including first and second areas receiving the first and second area reflected light beams respectively, a light mixer including a light mixer first area and a light mixer second area receiving a light beam from the first area and a light beam from the second area respectively, and a controller electrically connected to the array optical switch and controlling the array optical switch, so that the light mixer first area outputs a first color light, and the light mixer second area outputs a second color light. A method of using the system is also provided.

Abstract: The present disclosure provides a method for treating hypertension by using a compound, wherein the compound is selected from the group consisting of: (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide, and a combination thereof. The present disclosure uses a small molecule compound (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide or a combination thereof, which can be developed as a therapeutic drug for lowering blood pressure, whether it is taken orally or injected.

Abstract: A chemotherapy drug-sensitizing method includes: transfecting antisense oligonucleotide (e.g., siRNA-1976 or antagomir-1976) to a cancer cell to form a transfected cancer cell for blocking miR-1976 of the cancer cell; providing a treatment of cancer drug (or anticancer drug combination) to the transfected cancer cell whose miR-1976 is blocked by the antisense oligonucleotide; the transfected cancer cell providing a degree of sensitivity for the cancer drug due to its miR-1976 being blocked.

Abstract: The present invention provides a human-computer interactive rehabilitation system, which can automatically calculate rehabilitation strength suitable for the patient, so that it is not necessary to manually evaluate and adjust the parameter settings in human-computer interactive rehabilitation system when different patients use it. At the same time, the human-machine interactive rehabilitation system and the hospital end can track the rehabilitation status and intervene through the data platform at any time. The platform establishes a cloud community feedback and encouragement mechanism, and immediately transmits the rehabilitation results to the designated barriers of the patients, provides patient encouragement feedback, and strengthens the community interaction and linkage in the medical relationship.

Abstract: A chemotherapy drug-sensitizing method includes: transfecting antisense oligonucleotide (e.g., siRNA-1976 or antagomir-1976) to a cancer cell to form a transfected cancer cell for blocking miR-1976 of the cancer cell; providing a treatment of cancer drug (or anticancer drug combination) to the transfected cancer cell whose miR-1976 is blocked by the antisense oligonucleotide; the transfected cancer cell providing a degree of sensitivity for the cancer drug due to its miR-1976 being blocked.

Abstract: The present invention relates to a forgery detection system and its method for biomedical experiment images, especially for molecular-biological experiment images, such as western blot (WB) and polymerase chain reaction (PCR) results. The forgery detection system mainly comprises a processing module, an image difference computing module, a thresholding module, and an image mixing module are formed in an image analyzing device in the form of a library, a variable or an operand. Moreover, the processing module has a quantization parameter establishing unit, a similar computing unit, and a pseudo background generating unit. The purpose of the image analyzing device is to display an artificial image on the input image.

Abstract: A speaker diaphragm structure is installed inside a sound generator device which comprises a frame, a speaker diaphragm structure installed within the frame and a suspension edge whose inner perimeter is connected to the speaker diaphragm structure and whose outer perimeter is connected to the frame; herein the speaker diaphragm structure includes a diaphragm body and a composite material layer, in which the composite material layer is used for bonding onto the surface of the diaphragm body or attaching within the diaphragm body; moreover, the composite material layer is composed of one or more types of tetrapyrrole compounds as well as one or more types of metal ions; additionally, the composite material layer has a thickness smaller than the thickness of the diaphragm body, and is mainly applied to provide the performance effect of sound quality modifications.

Abstract: Disclosed is a metal gradient-doped cathode material for lithium ion batteries including a hexagonal-crystalline material body and a modifying metal. The metal gradient-doped cathode material is formed by coating modifying metal hydroxide on the surface of the hexagonal-crystalline material using a chemical co-precipitation method, then sintering the modifying metal hydroxide coated hexagonal-crystalline material. The modifying metal is different from the active metals, more concentrated on the surface, and gradually decreases toward the core of particle. A gradient-doped distribution is formed without any boundary or layered structure in the particle. The surface of the powder with more the modifying metal can effectively reduce the reactivity of the cathode material with the electrolyte in the lithium battery.

Abstract: A lithium nickel cobalt manganese composite oxide cathode material includes a plurality of secondary particles. Each secondary particle consists of aggregates of fine primary particles. Each secondary particle includes lithium nickel cobalt manganese composite oxide, which is expressed as LiaNi1-b-cCobMncO2. An average formula of each secondary particle satisfies one condition of 0.9?a?1.2, 0.08?b?0.34, 0.1?c?0.4, and 0.18?b+c?0.67. The lithium nickel cobalt manganese composite oxide has a structure with different chemical compositions of primary particles from the surface toward core of each of the secondary particles. The primary particle with rich Mn content near the surface and the primary particle with rich Ni content in the core of the secondary particle of the lithium nickel cobalt manganese composite oxide cathode material have provided the advantages of high safety and high capacity.

Abstract: An electrode structure of a vanadium redox flow battery is disclosed, which includes a proton-exchange membrane, two graphite papers, two graphite felt units, two pads, two graphite polar plates, two metal plates and a lock-fixing device which are symmetrically stacked in sequence from center to outside. wherein each graphite polar plate has the flow channels with a grooved structure, and each graphite felt unit is embedded in the flow channels of one of the graphite polar plates, and then the graphite felt units are covered by the graphite papers such that the different electrolytes flow in their corresponding flow channels. The storage tanks of vanadium electrolyte are connected through the connection pipelines, and the redox reaction is performed through the flows of the vanadium electrolyte. The electrode structure of the vanadium redox flow battery can be stacked for forming a large-scale electrode structure to increase the electrical power.

Abstract: An oil generation system is provided. The oil generation system includes a saccharide; and a working microorganism reacting with the saccharide to produce an oil, wherein the working microorganism has a genus being a Cystofilobasidium.

Abstract: A lithium nickel cobalt composite oxide cathode material includes a plurality of secondary particles. Each secondary particle consists of aggregates of fine primary particles. Each secondary particle includes lithium nickel cobalt composite oxide, which is expressed as LiaNi1-bCobO2. An average chemical formula of each secondary particle satisfies one condition of 0.9?a?1.2, 0.1?b?0.5. The lithium nickel cobalt composite oxide has a structure with different chemical compositions of primary particles from the surface toward core of each of the secondary particles. The primary particle with rich Co content near the surface and the primary particle with rich Ni content in the core of secondary particle of the lithium nickel cobalt composite oxide cathode material have provided the advantages of high safety and high capacity.

Abstract: A lithium nickel cobalt manganese composite oxide cathode material includes a plurality of secondary particles. Each secondary particle consists of aggregates of fine primary particles. Each secondary particle includes lithium nickel cobalt manganese composite oxide, which is expressed as LiaNi1?b?cCobMncO2. An average formula of each secondary particle satisfies one condition of 0.9?a?1.2, 0.08?b?0.34, 0.1?c?0.4, and 0.18?b+c?0.67. The lithium nickel cobalt manganese composite oxide has a structure with different chemical compositions of primary particles from the surface toward core of each of the secondary particles. The primary particle with rich Mn content near the surface and the primary particle with rich Ni content in the core of the secondary particle of the lithium nickel cobalt manganese composite oxide cathode material have provided the advantages of high safety and high capacity.

Abstract: The present invention discloses a method of inhibiting increase of immunoglobulin A, comprising a step of administering an effective amount of a pharmaceutical composition comprising ?-glucan and at least one pharmaceutically acceptable carrier to a subject in need.

Abstract: A compound used to prevent diseases caused by aquaporin deficiency, which is 18?-Glycyrrhetinic acid derivative. Said compound can not only prevent diseases caused aquaporin deficiency, but be able to prevent aquaporin (AQP) production and enhance skin function. Since AQPs have many advantages in skin cells, e.g. promoting water and glycerine molecular transportation, increasing skin elasticity and cuticle moisture, increasing the cell proliferation and cell migration, aquaporin can promote skin bather function and wound cicatrization. Therefore, said compound can be applied potentially as a medicinal cosmetic in skin medicine cosmetology, or as a new medical composition to treat diseases caused by AQP abnormality, such as urine concentration defect, wound healing slow down, corneal re-epithelialization slow down and etc.

Abstract: A use of a nucleic acid molecule mediating RNA interference for treating or reducing pain is disclosed. The nucleic acid molecule has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, and is used for effectively inhibiting expression of bradykinin B2 receptor, treating or reducing pain and preparing a pharmaceutical composition for reducing neuropathic pain.

Abstract: A use of a nucleic acid molecule mediating RNA interference for treating or reducing pain is disclosed. The nucleic acid molecule has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, and is used for effectively inhibiting expression of bradykinin B2 receptor, treating or reducing pain and preparing a pharmaceutical composition for reducing neuropathic pain.

Abstract: A compound used to prevent diseases caused by aquaporin deficiency, which is 18?-Glycyrrhetinic acid derivative. Said compound can not only prevent diseases caused aquaporin deficiency, but be able to prevent aquaporin (AQP) production and enhance skin function. Since AQPs have many advantages in skin cells, e.g. promoting water and glycerine molecular transportation, increasing skin elasticity and cuticle moisture, increasing the cell proliferation and cell migration, aquaporin can promote skin bather function and wound cicatrization. Therefore, said compound can be applied potentially as a medicinal cosmetic in skin medicine cosmetology, or as a new medical composition to treat diseases caused by AQP abnormality, such as urine concentration defect, wound healing slow down, corneal re-epithelialization slow down and etc.

Abstract: The present invention relates to the use of a composition made from Clerodendrum for treating tic disorder or sensorimotor gating deficits, wherein the composition is particularly made from the leaves of the plant.

Abstract: A method for producing oil by using yeast is provided. The method comprises utilizing at least one yeast strain serving as a working microorganism to produce the oil, wherein the yeast strain is genus Pseudozyma.